Published: November 16, 2026

Lp(a)HORIZON: Results of Landmark Clinical Trial Presented at AHA 2026

The results of the landmark Phase III Lp(a)HORIZON clinical trial were presented on 7 November 2026 at the American Heart Association (AHA) Scientific Sessions and simultaneously published in the New England Journal of Medicine (NEJM). The trial investigated whether a new experimental medicine, pelacarsen, could reduce the risk of cardiovascular events, such as heart attacks and strokes, in people with elevated lipoprotein(a), or Lp(a), who already had cardiovascular disease. The results showed that although pelacarsen substantially lowered Lp(a) levels, it did not reduce the risk of major cardiovascular events (MACE) compared with placebo (an inactive treatment). 

Background: From the initial announcement to the full trial results 

On 4 September 2026, Novartis announced that the Phase III Lp(a)HORIZON trial had not met its primary cardiovascular endpoint, despite substantially lowering Lp(a) levels. On 7 September, the Lp(a) International Task Force (ITF) issued an independent statement, emphasising the importance of awaiting the complete scientific results, including individual cardiovascular outcomes and subgroup analyses, before drawing definitive conclusions. On 16 October, Novartis informed patient organisations of its decision to discontinue the pelacarsen clinical development programme for atherosclerotic cardiovascular disease. FH Europe Foundation shared the company's official communication with the wider community, following a dedicated online discussion with Lp(a) Ambassadors, Patient Council representatives, clinical trial participants, joined by Prof. Florian Kronenberg, Chair of the Lp(a) International Task Force. With the detailed results now presented at AHA 2026 and published in peer-reviewed scientific journals, FHEF wishes to provide this accessible summary of the trial findings, including cardiovascular outcomes, subgroup results and reported side effects. 

About the Lp(a)HORIZON trial 

Lp(a)HORIZON was a large international clinical trial sponsored by Novartis, involving 8,323 participants across 797 clinical sites in 42 countries. All participants had elevated Lp(a) levels of at least 70 mg/dL and established cardiovascular disease, meaning they had previously experienced a heart attack, ischaemic stroke or symptomatic peripheral artery disease. Participants were aged 18–80 years, with an average age of approximately 60 years. Around 27% were women. Participants were randomly assigned to receive either: 

  • Pelacarsen: an experimental Lp(a)-lowering medicine, administered by injection once a month. 
  • Placebo: an inactive injection administered on the same schedule. 

The study followed participants for a median of 4.7 years. The primary objective was to determine whether lowering Lp(a) with pelacarsen could prevent further major cardiovascular events, including cardiovascular death, non-fatal heart attack, non-fatal stroke or an urgent procedure to restore blood flow to the heart. 

Importantly, participants were already receiving treatment to reduce their cardiovascular risk, including cholesterol-lowering medicines and other recommended therapies. The trial investigated whether adding pelacarsen to their existing treatment could provide further protection against cardiovascular events. 

Elevated Lp(a) is a recognised, genetically determined cardiovascular risk factor. The Lp(a)HORIZON trial specifically investigated whether lowering Lp(a) with pelacarsen could reduce further cardiovascular events in people who already had cardiovascular disease. 

The main results 

  1. Pelacarsen substantially lowered Lp(a) levels: After 12 months of treatment, pelacarsen reduced Lp(a) levels by approximately 78%, demonstrating a strong effect on the targeted blood marker.
  2. No reduction in major cardiovascular events was observed: Despite this substantial reduction in Lp(a), the trial did not demonstrate a reduction in major cardiovascular events. During the study, at least one major cardiovascular event occurred in:
  • 12.3% of participants receiving pelacarsen (511 people). 
  • 12.1% of participants receiving placebo (503 people). 

The difference between the two groups was not statistically significant. 

  1. Results were similar among people with particularly high Lp(a): Researchers also examined participants with Lp(a) levels of at least 90 mg/dL. In this group, major cardiovascular events occurred in 12.3% of participants in both treatment groups. No significant benefit was demonstrated in this subgroup.
  2. No significant differences were observed in other cardiovascular outcomes: The study also examined cardiovascular death, heart attacks, strokes and other cardiovascular outcomes. The results did not demonstrate a significant reduction in these outcomes with pelacarsen compared with placebo. Deaths from any cause occurred in 5.7% of participants receiving pelacarsen and 5.9% receiving placebo.

Safety and reported adverse events 

The trial also assessed the safety and tolerability of pelacarsen. Several adverse events were reported more frequently among participants receiving pelacarsen than those receiving placebo. 

Reported adverse event or reaction  Pelacarsen  Placebo 
Injection-site reactions  25.6%  2.9% 
Flu-like symptoms and general reactions  31.9%  5.8% 
Hypersensitivity reactions reported by investigators  17.1%  5.4% 
Adverse event suspected to be related to pelacarsen or placebo  56.8%  18.0% 
Adverse events leading to treatment discontinuation  20.6%  7.5% 
Serious adverse events from any cause  37.3%  41.1% 
Serious adverse event suspected to be related to pelacarsen or placebo  1.9%  0.2% 

Researchers also reported 19 cases of confirmed or probable anaphylaxis (0.5%) among participants receiving pelacarsen, compared with none in the placebo group. Anaphylaxis is a potentially life-threatening allergic reaction requiring urgent medical attention. Eight participants receiving pelacarsen were hospitalised following allergic reactions. No deaths from these reactions were reported. Following a suspected anaphylactic reaction during the trial in 2023, additional safety precautions were temporarily introduced, requiring injections to be administered under medical supervision. Adverse event suspected to be related to pelacarsen or placebo were 3 times higher in the pelacarsen group when compared to placebo (56.8% versus 18.0%). Overall, serious adverse events from any cause were reported in 37.3% of participants receiving pelacarsen and 41.1% receiving placebo, but 1.9% and 0.2% were suspected to be related to pelacarsen or placebo, respectively. 

In clinical trials, a serious adverse event is a medical occurrence that meets specific criteria, such as requiring hospitalisation or being life-threatening. It does not necessarily mean that the event was caused by the medicine being studied. The findings also showed that adverse events suspected to be related to treatment were reported more frequently in the pelacarsen group than in the placebo group (56.8% versus 18.0%). Treatment discontinuation due to adverse events was also more common among participants receiving pelacarsen (20.6% versus 7.5%). These findings provide important information about the safety and tolerability of pelacarsen. Whether other Lp(a)-lowering medicines currently being investigated will demonstrate different cardiovascular outcomes remains to be established through ongoing clinical trials. 

For people living with elevated Lp(a) 

Importantly, the Lp(a)HORIZON findings do not change existing recommendations for Lp(a) testing, cardiovascular risk assessment and prevention. Elevated Lp(a) remains a recognised, genetically determined cardiovascular risk factor. As outlined in the European Atherosclerosis Society (EAS) consensus statement, measuring Lp(a) at least once in adulthood remains an important part of cardiovascular risk assessment. 

Knowing a person's Lp(a) level helps healthcare professionals better understand their overall cardiovascular risk and guide the intensity of preventive measures, including the management of other risk factors such as LDL cholesterol, blood pressure, diabetes and smoking. The Lp(a)HORIZON findings do not call these recommendations into question. Rather, they highlight that we still need evidence from ongoing clinical trials to determine whether medicines specifically designed to lower Lp(a) can also reduce cardiovascular events. 

For people living with elevated Lp(a), the message remains clear: knowing your Lp(a) level matters, and managing your overall cardiovascular risk remains essential. The results of one trial should not discourage people from getting tested or discussing appropriate preventive care with their healthcare professionals. 

Our commitment to the Lp(a) community 

FH Europe Foundation acknowledges the invaluable contribution of the thousands of trial participants, their families, clinical teams and researchers whose commitment made this important international study possible. 

Building on our earlier engagement with Lp(a) Ambassadors, Patient Council representatives and clinical trial participants, FHEF remains committed to providing clear, accessible and independent information, facilitating dialogue with scientific experts, and ensuring that the voices and experiences of people living with elevated Lp(a) continue to inform discussions about cardiovascular prevention and future research.  

Looking ahead, FHEF is planning a dedicated community session in January 2027, bringing together people living with elevated Lp(a), clinical trial participants and scientific experts to discuss the Lp(a)HORIZON findings, address questions and provide further explanations in accessible language. Additional information will be shared through FHEF's communication channels. 

 

Additional analyses published 

Alongside the main results, researchers published further analyses in NEJM Evidence on 7 November 2026. These examined whether the findings differed according to treatment duration, uninterrupted treatment, the extent of Lp(a) reduction, participants' initial cardiovascular risk, or the number of cardiovascular events experienced. These additional analyses also found no evidence of a reduction in major cardiovascular events with pelacarsen. 

Further information 

The full results are available in two peer-reviewed scientific publications: 

  • Main clinical trial results: Cho L, Nicholls SJ, Frndak S, et al. Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a). N Engl J Med. Published online November 7, 2026. https://doi.org/10.1056/NEJMoa2610159 
  • Additional analyses: Nissen SE, Cho L, Frndak S, et al. Extended Analyses of Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a). NEJM Evid. Published online November 7, 2026. https://doi.org/10.1056/EVIDoa2600373 

For those wishing to learn more about the scientific context and the questions arising from the Lp(a)HORIZON results, we also invite readers to explore: 

  • Family Heart Foundation webinar – 19 November 2026, 18:00 CET: A dedicated discussion of the Lp(a)HORIZON findings featuring Dr Steven Nissen and Dr Harpreet Bhatia, providing an opportunity for the community to hear from cardiovascular experts and learn more about the results. Register here.  

 

Prepared by FH Europe Foundation in collaboration with Prof. Florian Kronenberg

Share:
Back to all News